Pharmaceutical company Emcure Pharma announced a healthy set of numbers in the June quarter of financial year 2027 (Q1FY27).
The company's net profit surged 42% year-on-year (YoY) to Rs 294 crore in the June quarter of FY27, as against Rs 207 crore in the June quarter of FY26.
ALSO READ: Swiggy's FY31 Growth Blueprint Lifts Shares 6%; Targets Rs 10,000 Crore EBITDA
Topline, or revenue gained 22.8% YoY to Rs 2,580 crore in Q1FY27, from Rs 2,101 crore in Q1FY27.
At the operating front, earnings before interest, tax, depreciation and amortisation (Ebitda) surged 27.8% YoY to Rs 533 crore in Q1FY27, from Rs 417 crore in Q1FY26.
Subsequently, EBITDA Margin expanded 90 basis points (bps) to 20.7% in the June quarter of financial year 2027, as against 19.8% a year ago.
The Board also appointed chief executive officer Satish Mehta as Chairman.
Founded in 1981 by Satish Mehta, Emcure Pharmaceuticals is a Pune-based Indian pharmaceutical company with a presence in more than 70 countries, including markets across Europe and Canada.
The company develops, manufactures and markets a wide range of pharmaceutical products, including tablets, capsules, liquids and complex injectables.
Its portfolio spans key therapeutic areas such as gynaecology, cardiology, oncology and HIV/AIDS, while it also has capabilities in biologics, active pharmaceutical ingredients (APIs) and iron formulations.
ALSO READ: CarTrade Tech FY26 Profit Jumps 68%, But Can Growth Justify Its Valuation?
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
